![Pinterest](https://pinterest.com/pin/create/button/?url=https://bollspel.com/hyris-and-ulisse-biomed-join-forces-to-create-a-powerful-new-global-biotech-group/&media=https://bollspel.com/wp-content/uploads/2024/01/16239-hyris-and-ulisse-biomed-join-forces-to-create-a-powerful-new-global-biotech-group.jpg&description="Hyris and Ulisse Biomed have combined their expertise to form a dynamic new global biotech group. Discover how this powerful collaboration is poised to make a significant impact in the biotech industry."){kind=link}
LONDON, Jan 15, 2024 – (ACN Newswire) – Exciting news in the biotech world! A dynamic new international biotech group has emerged from the fusion of renowned companies Hyris Ltd and Ulisse Biomed S.p.A., also known as UBM Group.
Hyris Ulisse Corporate Integration – A new benchmark in the biotech market
On December 21st, the integration between Hyris and Ulisse Biomed was officially ratified, marking a new era in genetic analysis and diagnostic solutions. The new Group, with a focus on diagnostics, teranosis, and healthcare, seeks to lead in the in-vitro diagnostics industry, particularly molecular biology.
Matteo Petti, CEO of Ulisse Biomed, expressed excitement about the integration, emphasizing the combined strengths of the two companies and the enhanced product offering that will result from the merger. The new structure aims to provide an integrated array of high-end products at a competitive cost, catering to diverse industry demands across global markets.
Stefano Lo Priore, founder of Hyris and Chairman of UBM Group, echoed this sentiment, expressing pride in the integration. The united company is poised to deliver a unique and distinctive offer on the global and Italian biotech scene. The future looks bright as the two companies pool their competencies to tackle new challenges.
Stay tuned for further updates as the new management implements a strategic plan to accelerate team and resource integration in the coming months.